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 70 
Statement of clinical relevance: The prospective randomized EORTC 26082 trial 71 
assessed the tolerability and efficacy of the mechanistic target of rapamycin (mTOR) 72 
inhibitor temsirolimus in patients with newly diagnosed, O6 methlyguanine-DNA-73 
methlytransferase (MGMT) promoter unmethylated glioblastoma. Temozolomide could be 74 
omitted without detriment in the experimental arm.  Efficacy of radiotherapy plus 75 
temsirolimus failed to reach the pre-specified number of patients alive at 12 months. Pre-76 
specified assessment of activity in the mTOR pathway allows to suggest that one third of 77 
patients with phosphorylated mTOR at Ser2448 derive a robust and clinically relevant 78 
survival benefit and will be candidates for clinical development of temsirolimus as a targeted 79 
therapy in a molecularly defined subgroup.  80 
 81 
82 
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ABSTRACT  83 
 84 
Purpose: EORTC 26082 assessed the activity of temsirolimus in patients with newly 85 
diagnosed glioblastoma harboring an unmethylated O6 methlyguanine-DNA-86 
methlytransferase (MGMT) promoter.   87 
Patients and Methods: Patients (n=257) fulfilling eligibility criteria underwent central MGMT 88 
testing. Patients with MGMT unmethylated glioblastoma (n=111) were randomized 1:1 89 
between standard chemo-radiotherapy with temozolomide or radiotherapy plus weekly 90 
temsirolimus (25 mg). Primary endpoint was overall survival at 12 months (OS12). A positive 91 
signal was considered >38 patients alive at 12 months in the per protocol population. A non-92 
comparative reference arm of 54 patients evaluated the assumptions on OS12 in a standard-93 
treated cohort of patients. Pre-specified post hoc analyses of markers reflecting target 94 
activation were performed. 95 
Results: Both therapies were administered per protocol with a median of 13 cycles of 96 
maintenance temsirolimus. Median age was 55 and 58 years in the temsirolimus and 97 
standard arms, the WHO performance status 0 or 1 for most patients (95.5%). In the per 98 
protocol population, 38 of 54 patients treated with temsirolimus reached OS12. The actuarial 99 
1-year survival was 72.2% [95% CI (58.2-82.2)] in the temozolomide arm and 69.6% [95% 100 
CI (55.8-79.9)] in the temsirolimus arm [HR=1.16, 95% CI (0.77-1.76), p=0.47]. In 101 
multivariable prognostic analyses of clinical and molecular factors phosphorylation of 102 
mTORSer2448 in tumor tissue (HR=0.13, 95% CI (0.04-0.47), p=0.002), detected in 37.6%, 103 
was associated with benefit from temsirolimus.    104 
Conclusions: Temsirolimus was not superior to temozolomide in patients with an 105 
unmethylated MGMT promoter. Phosphorylation of mTORSer2448 in the pretreatment tumor 106 
tissue may define a subgroup benefitting from mTOR inhibition. 107 
 108 
109 
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INTRODUCTION  110 
 111 
The serine/threonine kinase, mechanistic target of rapamycin (mTOR) serves as a hub 112 
integrating multiple intra- and extracellular cues in cancer cells (1). mTOR is involved in the 113 
formation of two multi-protein complexes, mTORC1 and mTORC2, that direct cell 114 
metabolism, growth, proliferation, survival, and angiogenesis.  115 
Preclinical studies suggested an enhanced activity of mTOR inhibition in PTEN-deficient 116 
tumour models (2, 3).  117 
Activation of the PI3K/AKT/mTOR pathway has been associated with reduced survival of 118 
glioma patients (4) and this signalling pathway has been subjected to a number of negative 119 
single- or multi-targeted therapies including the mTOR inhibitor rapamycin or its derivatives, 120 
the ‘rapalogs’ everolimus (RAD001), deforolimus (AP23573), and temsirolimus (CCI-779) (5-121 
9).  122 
The experience with temozolomide (TMZ) teaches that limited activity at recurrence (10) 123 
may still relevantly modify the disease in patients with newly diagnosed glioblastoma when 124 
combined with radiotherapy (11). Accordingly, mTOR inhibition has been considered an 125 
option for patients with treatment-naïve glioblastomas that likely lack some of the 126 
mechanisms of resistance acquired at recurrence.  127 
Temsirolimus (Torisel®) has been approved for advanced renal cell carcinoma (12) and 128 
relapsed or refractory mantle cell lymphoma (13). Additive effects of temsirolimus plus 129 
radiotherapy (RT) in preclinical models demonstrate that temsirolimus could complement the 130 
genotoxic activity of RT in the treatment of newly diagnosed glioblastoma. However, 131 
combination of TMZ and temsirolimus plus RT was too toxic (14).  132 
Therefore, the rationale of this study was to test the biological effects of mTOR inhibition 133 
when combined with ionizing radiation in patients in whom TMZ could be safely omitted. To 134 
this end patients with tumors with an unmethylated O6 methlyguanine-DNA-135 
methlytransferase (MGMT) gene promoter were selected for the trial, as they derive little if 136 
any benefit from the addition of TMZ (15). Another aim was to identify biological factors, i.e. 137 
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biomarkers linked to benefit from mTOR inhibition. Temsirolimus may counteract therapy-138 
induced angiogenesis and invasion (16, 17).  139 
140 
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PATIENTS AND METHODS 141 
 142 
Clinical Trial 143 
Study design and treatment 144 
Patients for EORTC 26082 (NCT01019434) were recruited at 14 study sites in 10 countries 145 
in Europe. First, patients were registered after consenting for independent pathology review 146 
and central testing of the MGMT promoter methylation status by licensed laboratories of 147 
MDxHealth (Herstal, Belgium) using quantitative methylation-specific polymerase chain 148 
reaction of DNA isolated from macro-dissected formalin fixed paraffin embedded tumor 149 
sections (18). Patients were considered MGMT unmethylated, applying a safety margin, 150 
when the ratio of MGMT to the control gene ACTB was < 0·6, calculated as (methylated 151 
MGMT/ACTB)×1000. This corresponds to the lower bound of the 95% confidence interval 152 
established in a cohort of 602 glioblastoma samples screened in the CENTRIC trial where 153 
the cut-off corresponding to the established nadir was at a ratio of 2 that separates 154 
methylated from unmethylated. (19) as visualized in Supplementary Figure S1. A minimum 155 
of 1,250 copies of ACTB were required for a valid result, unless the copy number for 156 
methylated MGMT was ten or more, which was scored as MGMT methylated.  157 
Eligible patients (see Supplementary Information) were randomly assigned to receive 158 
either standard chemoradiotherapy (TMZ/RTTMZ) (11), or standard fractionated RT with 159 
concomitant temsirolimus (standard dose of 25 mg i.v. weekly beginning at day -7 from the 160 
start of RT, to be continued until disease progression) (Figure 1 and Supplement). The 161 
study was conducted according to the Declaration of Helsinki, the International Conference 162 
on Harmonisation note for good clinical practice (Topic E6, 1996), and regulatory 163 
requirements. 164 
This study was funded by a grant from Pfizer, Berlin, Germany (details on the Role of the 165 
Funding Source in the Supplement). 166 
 167 
Randomisation and masking  168 
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Randomisation was performed centrally using an interactive voice response system. 169 
Patients were stratified according to age, WHO performance status and baseline steroids. 170 
As this was an open-label study, no blinding procedures were applied. 171 
 172 
Study endpoints 173 
The primary endpoint was overall survival at 12 months (OS12) to avoid issues around 174 
pseudoprogression and generate a timely signal. Secondary endpoints included 175 
progression-free survival (PFS), OS, safety and assessment of prognostic and predictive 176 
biomarkers. 177 
  178 
Outcome measures and statistical analyses 179 
OS12 was defined as the fraction of patients alive at 12 months from randomisation; PFS 180 
was defined as duration from randomisation until first observation of PD or death from any 181 
cause or censored at last disease assessment without progression or start of second anti-182 
cancer therapy; OS was defined as time from randomisation until death or last visit. 183 
PFS was assessed locally by investigators according to the Macdonald criteria (20), in case 184 
of suspected pseudoprogression investigators were advised to continue treatment per 185 
protocol and repeat imaging after 1-2 months. If progression was confirmed, the date of first 186 
observation of tumor progress was used for the analyses. 187 
Adverse events (AEs) were coded according to the Medical Dictionary for Regulatory 188 
Activities version 15.0, and their severity was graded according to National Cancer Institute 189 
Common Terminology Criteria for Adverse Events version 3.0.  190 
A Fleming one-sample one-stage testing procedure was used in each arm. It was assumed 191 
that with OS12 lower or equal to 60% (P0) the therapeutic activity of temsirolimus (CCI-779) 192 
was too low(11). While a OS12 greater or equal to 80% (P1) implied that the therapeutic 193 
activity of temsirolimus (CCI-779) was adequate Type I (α) and II (β) errors were both equal 194 
to 5%. Under these hypotheses, a sample size of 54 eligible patients in each arm was 195 
EORTC 26082 Wick et al. Page 9 
  2/26/2016 
 
required. The decision rule was that if >38 eligible patients were alive at 1 year, it was 196 
concluded that the therapeutic activity of temsirolimus was adequate. 197 
All statistical analyses were performed on mature data (median follow-up 32 months) by 198 
Thierry Gorlia. The concept of a non-comparative control arm allows for adjustment of the 199 
initial assumptions based on contemporary control treatment. The trial would be insufficient 200 
to confirmatory declare efficacy. However, statistical comparisons are still valid and useful 201 
for hypothesis-generation and exploratory analyses. 202 
The OS12 was also computed in the TMZ/RT→TMZ arm in order to assess the consistency 203 
with P0.  204 
 205 
Biomarker substudy 206 
Tissue Micro Array, Immunohistochemistry and FISH EGFR 207 
Tissue micro arrays (TMA) were constructed using recipient paraffin blocks with an agarose 208 
matrix (21). Immunohistochemical analyses and Fluorescent In Situ Hybridization (FISH) 209 
were performed in duplicate on sections from 2 replicate TMAs basically as recommended 210 
by the manufacturers (see supplemental methods for antibody description, conditions and 211 
dilutions; FISH probes). Markers for post hoc analyzes of the mTOR pathway were pre-212 
specified in the protocol (phosphorylated S6 ribosomal protein, p-S6RPSer235/236; 213 
phosphorylated AKT, p-AKTSer473; PTEN; phosphorylated AKT1 Substrate 1 (proline-rich), 214 
p-PRAS40Thr246; phosphorylated extracellular signal-regulated linase, ERK1/2Thr202/Tyr204) or 215 
based on a more recent study (phosphorylated p-mTORSer2448) (22, 23). Scoring and 216 
definition of dichotomization is detailed in the Supplemental Methods.  217 
 218 
Multidimensional marker analysis 219 
The centered score table of the markers containing missing values was analysed by 220 
principal component analysis. Non-linear Iterative Partial Least Squares (NIPALS) algorithm 221 
(24) was used to perform singular-value decomposition with missing value and to complete 222 
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the data. A consensus hierarchical clustering analysis (25) based on Euclidean distance and 223 
Ward’s algorithm was used to investigate the optimal number of clusters. The association 224 
among marker scores was illustrated by network representation based on Spearman 225 
correlation. Analyses and graphical representations were performed using R-3.2.0 and the R 226 
packages mixOmics, qgraphs (26) and ConsensusClusterPlus. 227 
 228 
Statistical analysis 229 
The scores of the P-markers were dichotomized into negative (scores 0, 1, corresponding to 230 
0 to10%) vs positive (scores 2 to 5, >10%). Study stratification factors (age, WHO 231 
performance status, baseline steroids) and molecular markers were correlated to OS.  232 
Treatment arms were compared with a log-rank test at 5 % significance. For each of them, 233 
PFS and OS were estimated using the Kaplan-Meier (KM) method. Associations of marker 234 
profiles with treatment efficacy were presented by Forest Plot and significance was 235 
assessed with the test for interaction computed from a Cox model including the treatment, 236 
the marker and their interaction term. A 5% significance was used for screening predictive 237 
markers. For each factor, univariable survival estimates were calculated using the KM 238 
technique in the TMZ and temsirolimus arms. Hazard Ratios obtained from univariable Cox 239 
models were presented with 95 % Confidence Intervals (CI) (details in the Supplement).  240 
241 
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Overall, 257 patients were registered, screened for eligibility and assessed for MGMT 245 
promoter methylation status, whereof 28 patients were registered after screening through the 246 
CENTRIC trial that selected MGMT methylated patients only (19); 190 patients were found 247 
to have glioblastoma with an unmethylated MGMT promoter applying the cut-off with a 248 
safety margin (Figure S1). The primary reasons for initially registered patients not to 249 
continue to randomisation were hypermethylated MGMT status (n=67), withdrawal of 250 
consent (n=24), and other reasons (n=55), including insufficient tumor material (n=30), and 251 
AEs after surgery (n=8) (Figure 1). A total of 111 patients were randomised from December 252 
2009 through September 2012 and constituted the ITT population: 56 patients were 253 
scheduled to receive weekly temsirolimus in addition to standard RT (temsirolimus arm) and 254 
55 were to receive TMZ/RTTMZ alone (control arm). In the safety population, i.e. patients 255 
with at least one dose of drug, there were 53 patients in the temsirolimus and 51 patients in 256 
the TMZ arm. 257 
Median follow-up was 33 (95% CI: 23-37) months in the temsirolimus and 32 (95% CI: 22-258 
40) months in the TMZ arm. The median duration from operation to randomisation was 2.6 259 
weeks (range 0.4−6.1 weeks). Patient baseline and demographic characteristics were well 260 
balanced between treatment arms except for the WHO Performance status between PS0 261 
and PS1, which favored the control arm. This is explained since the stratification was PS 0-1 262 
vs PS2 (Table 1).  263 
In the biomarker cohort (n=88), only one patient sample displayed positive staining for the 264 
IDH1-R132H mutant (1/78; 1.3%), an expected low frequency, since 75% of the few IDH1 265 
mutant glioblastoma are MGMT hypermethylated (27). The frequency of EGFR amplification 266 
was in the expected range (54%, 44/82). There was no difference in baseline characteristics 267 
and outcome in patients with vs without markers assessment (Supplementary Figure S2, 268 
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Supplementary Table S1).  269 
 270 
Efficacy outcomes 271 
The median duration of radiotherapy was 6.1 weeks in both arms. Main reason for 272 
interrupting RT was technical or administrative (28%). In median, RT was interrupted 2 days. 273 
RT was completed by >90% of patients. Concomitant treatment was delivered as planned 274 
per protocol by >90% of patients in both arms. Patients in the temsirolimus arm received the 275 
drug for a median (95% CI) of 16 weeks post RT (4.0 – 84.3), with a mean dose intensity of 276 
21.4 (6.3 - 25) mg/week.  277 
Maintenance temsirolimus was administered per protocol at a median of 13 weekly cycles. 278 
Median relative dose-intensity was 85.6%. Twelve patients had a reduction in dose intensity 279 
below 70%, because of dose reduction (19.1%: 6.4% for hematological toxicity, 10.6% for 280 
AE, 2.1% for other reasons), dose not given during at least one cycle (68%: 6.3% for 281 
hematological toxicity, 34% for non-hematological toxicity, 58% for other reasons) or 282 
treatment delay (58%: 2.1% for hematological toxicity, 17% for non-hematological toxicity, 283 
43% for other reasons).  284 
Median OS was 14.8 (13.3-16.4) months in the temsirolimus arm and 16.0 (13.8-18.2) in the 285 
control arm (90 deaths; HR, 1.2; 95% CI, 0.8-1.8; p=0.47; Figure 2A). The OS12 and OS24 286 
rates did not differ between arms (70%, 72% and 15%, 16%, respectively). Median PFS as 287 
assessed by the investigator was 5.4 (95% CI, 3.7-6.1) months in the temsirolimus arm and 288 
6.0 (95% CI, 2.8-8.0) months in the control arm (54 PFS events; HR, 1.26; 95% CI, 0.86–289 
1.86; p=0.24; Figure 2B). In the per protocol population (see Supplementary Information), 290 
38 patients treated with temsirolimus had survived ≥ to 1 year. At least 39 patients were 291 
needed to reach the targeted drug activity.  292 
 293 
Safety 294 
In the temsirolimus arm severe hematological toxicity was: neutropenia (G3: n=1, 1.9%) and 295 
lymphocytopenia (G3: n=9, 16.4%, G4: n=1, 1.8%). In the TMZ arm severe hematological 296 
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toxicity was: leukopenia G3 (n=2, 3.8%), neutropenia G4 (n=2, 3.8%), lymphocytopenia (G3: 297 
n=14, 26.4%, G4: n=2, 3.8%) and thrombocytopenia (G3: n=1, 1.9%, G4: n=1, 1.9%). There 298 
was no other severe (G3/4) treatment-related AE with an incidence >5% in either arm.  299 
  300 
Molecular correlations with outcome 301 
Markers interrogated for their relevance of targeting the mTOR signaling pathway (22, 23) 302 
are visualized in the mTOR KEGG pathway (28) (Supplementary Figure S3). 303 
Phosphorylated mTORSer2448 was associated with prolonged OS as evidenced by the 304 
significant interaction term between treatment and p-mTORSer2448 (p=0.047, Figure 3). 305 
Tumors of 37.6% of the patients scored positive for p-mTORSer2448. There was a non-306 
significant trend for longer OS when p-mTORSer2448 positive patients received temsirolimus 307 
as compared with controls (HR=0.62, 95% CI 0.26-1·47, p=0.27). When non-phosphorylated 308 
mTORSer2448 patients received temsirolimus a non-significant decrease in survival was 309 
observed compared with controls (HR=1.77, 95% CI 0.95-3.29, p=0.07) (Figure 3). The 310 
median OS in the temsirolimus group was 17.8 months (CI, 14.1-28.0) for patients with p-311 
mTORSer2448 positive tumors and 13.1 months (CI, 9.7-15.1) in the negative subgroup 312 
(p=0.007, Figure 3A). In the RT/TMZ→TMZ control arm the median OS in the p-mTORSer2448 313 
positive group was 14.0 months (CI, 9.6-19.6) and 16.5 months (CI, 9.5-18.8) in the p-314 
mTORSer2448 negative subgroup (p=0.999). For p-PRAS40Thr246, the interaction test with 315 
treatment was borderline non-significant (p=0.07). The impact of all other markers on 316 
survival is illustrated in a forest plot for all other markers in Supplementary Figure S4.   317 
 318 
A multi dimensional analysis used the full range of the scores of the mTOR-associated 319 
markers integrated information for the identification of clinically relevant molecular subgroups 320 
and to gain further insights on pathway interactions (Figure 4). The two first axes obtained 321 
by PCA explained 57·8% of the total inertia. The first axis was mainly explained by p-322 
mTORSer2448 and p-PRAS40Thr246. The p-S6RPSer235/236 mainly contributed to the construction 323 
of the second axis (Figures 4E and F). PTEN expression played a minor role in the 324 
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structure of the score table (Figure 4F). Subgroups were determined by consensus 325 
clustering. We kept the cluster based on two groups (k=2) by default, as no strong indication 326 
for the optimal number of clusters was obtained and the sample size is limited 327 
(Supplementary Figure S5). Cluster 2, highly enriched for p-mTORSer2448-positive cases, 328 
revealed a strong association with outcome in the temsirolimus treatment group and no 329 
difference in the TMZ/RTTMZ group (Figure 4). Significant interaction was observed with 330 
treatment (p=0.009): in Cluster 2 the HR was 0.42 (95% CI 0.15-1.13, p=0.08) and in Cluster 331 
1 HR=1.77 (95% CI 0.96-3.25, p=0.06).  332 
In multivariable prognostic analyses of clinical and molecular factors (Supplementary Table 333 
S1), p-mTORSer2448 (HR=0.13, 95% CI 0.04-0.47, p=0.002), p-PRAS40Thr246 (HR=0.50, 95% 334 
CI 0.21-1.18, p=0.12), p-ERKThr202/Tyr204 (HR=2.81, 95% CI 0.97-8.09, p=0.06), but no clinical 335 
factor was associated with OS in the temsirolimus arm. The PEV was equal to 14.9% In the 336 
TMZ arm, there was a trend for decreased survival in p-AKTSer473 positive patients (HR=3.21, 337 
95% CI 0.89-11.56, p=0.07, PEV=4.5%). None of the models had a PEV larger than 20%. 338 
339 
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This randomized, open label phase II trial investigating the mTOR inhibitor temsirolimus in 342 
combination with RT for patients with low probability of benefit from the TMZ-based 343 
radiochemotherapy failed to demonstrate the targeted outcome. Neither PFS nor OS 344 
demonstrated a signal of relevant activity in the total trial population (Figure 2). Safety and 345 
tolerability of temsirolimus in combination with standard RT were non-concerning and the 346 
trial is an example that temozolomide can be safely omitted in patients with MGMT 347 
unmethylated glioblastoma. The trial proposes mTORSer2448 phosphorylation as a biomarker 348 
for benefit from mTOR inhibition. These results need further confirmation, and a trial to 349 
prospectively assess the relevance of this putative biomarker is underway (NCT Neuro 350 
Master Match, EudraCT 2015-002752-27). 351 
The good outcome data in both arms of the trial prompted a comparison with the 352 
EORTC26981-22981/NCIC CE3 trial. The comparison with our pivotal TMZ/RTTMZ vs RT 353 
trial (EORTC26981-22981/NCIC CE3) (29) was favourable in all aspects supporting the 354 
principal rational to design trials for patients with MGMT unmethylated glioblastoma and 355 
withhold TMZ in the experimental arm (Supplementary Results). Biases in favor of EORTC 356 
26082 may have been patient selection, and the lower number of patients on steroids (30). 357 
Bevacizumab was administered in about 45% of the patients in both arms of EORTC 26082. 358 
The OS of the EORTC 26082 arms is comparable to the outcome in the control arms of trials 359 
with selection of MGMT unmethylated patients, with 13.4 months in the CORE trial (95% CI 360 
12.2-14.3) with a bevacizumab use at recurrence of 22% (31) and 17.3 months (95%CI 14.8-361 
20.4 months) in the GLARIUS trial with cross over to bevacizumab of 60% (32). 362 
The EORTC 26082 trial aimed at not withholding TMZ from any patient with an equivocally 363 
methylated MGMT promoter by applying a MGMT cut-off with a safety margin. This 364 
prompted an adaption also in the GLARIUS trial (32) with similar design and therefore 365 
demarcates an evolution from the S039 trial with enzastaurin (33). Two randomized phase III 366 
trials in elderly patients with newly diagnosed glioblastoma further support a strictly 367 
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predictive effect of the MGMT status for benefit from TMZ (34, 35). However, we cannot 368 
completely exclude a small baseline effect of TMZ despite the MGMT unmethylated state 369 
(11). Hence, withholding TMZ outside trials and elderly patients with unmethlylated MGMT 370 
promoter is not advocated by the present data. In the temsirolimus arm 59% (n=33) of the 371 
patients received TMZ after treatment discontinuation, and 26% of TMZ patients (n=14) were 372 
re-challenged with TMZ, not being aware of the recent data from the DIRECTOR trial that re-373 
challenge with TMZ might be relevant only for patients with a methylated MGMT promoter 374 
(36). 375 
The choice of temsirolimus for patients with unmethylated glioblastoma was based on 376 
preclinical data already highlighting that not every tumor responds to the treatment (37) as 377 
well as a response may be only transient because of the overt feedback resistance 378 
mechanisms (22, 38).  379 
Molecular analyses of prespecified principal components of the EGFR-PI3-K/mTOR/AKT 380 
pathway were performed. EORTC 26082 provides first evidence that p-mTORSer2448 and – to 381 
a lesser extent - p-PRAS40Thr246 may serve as decisive biomarkers for the treatment of 382 
patients with newly diagnosed glioblastoma with an unmethylated MGMT promoter. 383 
Phosphorylation of mTORSer2448 has been shown to be targeted and blocked by rapamycin, a 384 
major metabolite of temsirolimus (39), while phosphorylated PRAS40Thr246 (substrate of 385 
AKT1) relieves inhibitory function on mTORC1 (40). The survival curves may even suggest 386 
that there is a detrimental effect of temsirolimus in p-mTORSer2448 negative tumors (Figures 3 387 
and 4). Previous trials testing temsirolimus at recurrence had focused on the PTEN status 388 
with a PTEN deficiency as a prerequisite for response (22) or on other downstream mTOR 389 
targets, e.g. p-S6RPSer235/236, which was neither associated with outcome in biomarker 390 
analyses of patients with recurrent glioblastoma receiving temsirolimus (6, 38) nor in this 391 
study. It cannot be excluded that glioblastomas treated at recurrence may have changed 392 
mTOR pathway activity as compared to tumor specimen used for marker analyses obtained 393 
at the first resection (41). Also, “paradoxical” activation of AKT by elimination of negative 394 
feedback downregulating survival signaling has been postulated as potential resistance 395 
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mechanism to mTOR inhibition in previous trials, based on the analyzes of paired tumor 396 
specimen taken before and after treatment (22, 38). Interestingly, trials in other diseases did 397 
not provide predictive biomarkers (12, 13). 398 
The limitations of EORTC 26082 are the relatively small sample size of this non-comparative 399 
phase II trial. For the biomarker analyses using IHC only a limited number of tumor tissue 400 
samples from the ITT cohort were available. The findings should be validated by evaluation 401 
of previous trials in particular in those treating newly diagnosed glioblastoma patients (42) 402 
and the randomized phase II study RTOG-0913. Ongoing trials using mTOR inhibitors may 403 
need to take into account a potentially detrimental effect in patients with an 404 
unphosphorylated mTORSer2448. Given the ongoing efforts of biomarker-driven basket trials 405 
for patients with newly diagnosed glioblastoma, the concept of mTOR inhibition using the 406 
marker predictive in this study, p-mTORSer2448 is incorporated into the design of a future 407 
study.  408 
 409 
410 
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FIGURE LEGENDS 566 
 567 
Figure 1. Supplemented CONSORT diagram of patient disposition.  568 
 569 
Figure 2. Principal efficacy outcomes per treatment.  570 
 571 
Figure 3. Overall survival according to phosphorylated mTOR stratified by treatment.  572 
(A) Kaplan-Meier curves shown represent patients separated by the phosphorylation status 573 
of mTORSer2448 (Pos, positive; Neg, negative) stratified for the two treatment arms CCI-574 
779/RT and TMZ/RTTMZ (TMZ). The interaction test was significant p=0.047). (B) 575 
Representative glioblastoma samples negative or positive for p-mTORSer2448 expression.  576 
 577 
Figure 4. Multidimensional analysis of m-TOR associated markers.  578 
The associations among markers in the mTOR pathway are illustrated by “The network 579 
representation” based on Spearman correlations between scores (A). (B) The glioblastoma 580 
subgroups based on mTOR pathway markers are visualized in a heatmap of the score table 581 
obtained after reconstruction using Non-linear Iterative Partial Least Squares (NIPALS). The 582 
rows were ordered by the first axis of the PCA. The columns are ordered by the consensus 583 
classification (k=2; clusters 1, blue; cluster 2, red) and are annotated for absence or 584 
presence of mutated IDH1R132H (positive, red; negative, grey; unknown; white), and the 585 
EGFR status (amplified dark green, non-amplified, green; unknown, white). The association 586 
between OS and consensus classification for two groups (k=2) (cluster 1, blue; cluster 2, 587 
red) is illustrated by Kaplan-Meier representation for patients randomized to CCI-779 (C) and 588 
TMZ (D). The p-value is given for each KM. The patients (E) and m-TOR-associated 589 
markers (F) were projected onto the two first components of the principal component 590 
analysis (PCA). Inertia ellipses and stars visualize the separation of the patients into the two 591 
groups obtained from consensus clustering (cluster 1, blue; cluster 2, red) (E).  592 










 N (%) N (%) N (%) 
Age                                                                          
 median        57.7              54.9             55.7            
 range           24.4 - 76.0       28.2 - 74.7       24.4 - 76.0       
Sex                                                                          
 male               36 (65.5)            35 (62.5)           71 (64.0)       
 female           19 (34.5)            21 (37.5)           40 (36.0)       
Extent of 
resection                
                                                
 open 
 biopsy         
   1 (1.8)              3 (5.4)             4 (3.6)         
 resection       54 (98.2)            53 (94.6)          107 (96.4)       
Corticosteroids                                                      
 no                  37 (67.3)            40 (71.4)           77 (69.4)       
 yes    18 (32.7)            16 (28.6)           33 (29.7)       
WHO PS (0-4)                                                         
 0                     40 (72.7)            32 (57.1)           72 (64.9)       
 1                     14 (25.5)            20 (35.7)           34 (30.6)       
 2                      1 (1.8)              4 (7.1)             5 (4.5)         
Abbreviations: TMZ, temozolomide; WHO PS, World Health Organization 
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O N Number of patients at risk : Treatment
44 55 52 39 18 6 3 1


















Median (95% CI) 
(Months) 
% at 1 Year 
(95% CI) 
TMZ 55 44 1.00 0.4708 16.03 (13.83, 18.20) 72.22 (58.22, 82.22) 

















O N Number of patients at risk : Treatment
51 55 27 9 5 2 2 1


















Median (95% CI) 
(Months) 
% at 0.5 Year(s) 
(95% CI) 
TMZ 55 51 1.00 0.2358 5.95 (3.25, 8.02) 50.00 (36.12, 62.39) 
CCI-779 56 54 1.26 (0.86, 1.86)  5.36 (3.71, 6.14) 38.67 (25.96, 51.20) 
 
Figure 2B















TMZ/p-mTOR Neg            23         19 16.46 (9.53, 18.79)           10.7 (1.8, 28.7)    1.00                0.042 (df=3)                                      
TMZ/p-mTOR Pos            16         13 14.01 (9.56, 19.55)           11.3 (0.9, 36.4)    0.99 (0.49, 2.01)                                                     
CCI-779/p-mTOR Neg         25         24 13.11 (9.66, 15.08)           4.0 (0.3, 17.0)     1.71 (0.93, 3.14)                                                     
CCI-779/p-mTOR Pos         13          9 17.77 (14.09, 27.99)          29.7 (7.4, 56.8)    0.59 (0.26, 1.32)                                                     
                                                                      Log-rank test:      p-value=0.041                                     
(months) 






O N Number of patients at risk : Trt/p-mTOR 
19 23 21 15 7 2 0 0 
13 16 16 12 5 1 1 0 
24 25 23 15 2 0 0 0 
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O N Number of patients at risk : Cons. cluster
25 26 24 16 3 0 0 0




Overall Score test: p=0.002
(months)












O N Number of patients at risk : Cons. cluster
20 24 22 16 9 2 0 0




Overall Score test: p=0.875
A
DC




























EORTC 26082 SUPPLEMENT Wick et al. Page 1 
  2/26/2016 
 
 
SUPPLEMENTARY INFORMATION TO 
 
Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with 
temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter 
hypermethylation (EORTC 26082) 
 
1,2Wolfgang Wick, 3Thierry Gorlia, 4,5Pierre Bady, 1,6Michael Platten, 7Martin J van den Bent, 
8Martin JB Taphoorn, 3Jonathan Steuve, 9Alba A. Brandes, 5,10Marie-France Hamou, 1Antje 
Wick, 11Markus Kosch, 13Michael Weller, 10Roger Stupp, 13Patrick Roth, 3Vassilis 
Golfinopoulos, 12Jean-Sebastien Frenel, 12Mario Campone, 14Damien Ricard, 15Christine 
Marosi, 16Salvador Villa, 17Astrid Weyerbrock, 18Kirsten Hopkins, 10Krisztian Homicsko, 
19Benoit Lhermitte, 20Gianfranco Pesce, 5,10Monika E Hegi 
 
1Neurology Clinic, University of Heidelberg and 2Clinical Cooperation Unit (CCU) 
Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center 
(DKFZ), Heidelberg, Germany; 3European Organisation for Research and Treatment of 
Cancer (EORTC); 4Swiss Institute of Bioinformatics, 5Neuroscience Research Center, 
University Hospital Lausanne (CHUV), both Lausanne, Switzerland; 6CCU Brain Tumor 
Immunology, DKFZ, Heidelberg, Germany; 7Department of Neurology/Neuro-Oncology, 
Erasmus MC - Cancer Institute, Rotterdam; 8Neuro-oncology Unit, MC Haaglanden, The 
Hague, both The Netherlands; 9Department of Medical Oncology, Ospedale Bellaria, 
Bologna, Italy; 10Departments of Neurosurgery and Oncology, Centre Hospitalier 
Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland; 11Pfizer, Berlin, 
Germany; 121-Institut de Cancérologie de l'OUEST, Saint Herblain-Nantes Cedex, France; 
13Department of Neurology, University Hospital and University of Zurich; 14Hopitaux de Paris 
- La Pitié Salpétrière, Paris, France; 15General Hospital AKH, Medical University Vienna, 
Austria; 16Institut Catala d’Oncologia (ICO). Hospital Germans Trias Pujol, Badalona, 
EORTC 26082 SUPPLEMENT Wick et al. Page 2 
  2/26/2016 
 
 
Barcelona, Spain; 17Neurosurgery Clinic, University Medical Center, Freiburg, Germany; 
18University Hospitals Bristol NHS Foundation Trust - Bristol Haematology and Oncology 
Centre, Bristol, U.K.; 19Institute of Pathology, CHUV, Lausanne; 20Department of Radio-
oncology, Oncology Institute of Southern Switzerland, Bellinzona; all Switzerland  
EORTC 26082 SUPPLEMENT Wick et al. Page 3 
  2/26/2016 
 
 
Supplementary Patients and Methods 
 
MGMT Testing 
In brief, DNA was isolated from formalin-fixed, paraffin-embedded tumour samples using 
macro-dissected sections; DNA was modified with sodium bisulfite and subjected to 
quantitative methylation-specific PCR using β-actin as a reference gene (ACTB).1  
 
Key eligibility criteria 
Patients aged ≥18 years with newly diagnosed, histologically confirmed supratentorial 
glioblastoma (WHO Grade IV), centrally determined unmethylated MGMT status, and with an 
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 were eligible. 
Additional inclusion criteria were: written informed consent; available tumour tissue from 
surgery or open biopsy (stereotactic biopsy was not allowed) for MGMT promoter 
methylation status analysis and central pathology review; gadolinium-enhanced (Gd) MRI 
performed within 48 hours post surgery, or alternatively, Gd-MRI performed before 
randomisation; stable or decreasing steroid doses for ≥5 days prior to randomisation; and 
adequate haematological, renal, and liver function. Key exclusion criteria were prior 
chemotherapy within the last 5 years, prior RT of the head, treatment with other 
investigational agents 30 days before first dose of temsirolimus, and prior systemic 
antiangiogenic therapy; history of coagulation disorder associated with bleeding or recurrent 
thromboembolic events; presence of QTc prolongation >450/470 msec (males/females); 
placement of Gliadel® wafers at surgery; history of malignancy within the last 5 years (except 
curatively treated cervical carcinoma in situ or basal cell carcinoma of the skin); clinically 
manifest cardiovascular insufficiency (NYHA III, IV) or myocardial infarction during the past 6 
months, and uncontrolled arterial hypertension. 
Patients randomized into the trial constituted the intention-to-treat population (n=55 control 
arm; n=56 temsirolimus arm). 
EORTC 26082 SUPPLEMENT Wick et al. Page 4 
  2/26/2016 
 
 
Patients having received at least one trial-specific treatment and fulfilling the basic eligibility 
criteria constituted the per-protocol-population (n=50 control arm; n=54 temsirolimus arm). 
Reasons for exclusion from the per-protocol population were no treatment (n=3), and QTc or 
laboratory value deviations in the baseline criteria that should have prevented inclusion into 
the trial (n=5). One patient fulfilled two reasons not to be counted for the per-protocol-
population. 
The safety population excluded only patients that never received any study-specific therapy 
(n=3) and resulted in 53 patients in the control arm and 55 patients in the temsirolimus arm.  
 
Treatment 
Each treatment with temsirolimus was to be preceded by supportive medication with a 
histamine H2-receptor antagonist. RT consisted of 3D conformal radiotherapy and was given 
at 2 Gy per fraction, 5 days/week, for up to 6 weeks and to a total dose of 60 Gy; TMZ 75 
mg/m2 was administered orally 7 days/week throughout RT, thereafter, starting 4 weeks after 
the end of RT (week 11) TMZ 150–200 mg/m2 was administered for 5 consecutive days 
every 4 weeks for 6 cycles. Temsirolimus was to be continued until disease progression (PD) 
or unacceptable toxicity. Crossover from the control to the temsirolimus arm was not allowed. 
Temsirolimus was administered as 30-minute infusion starting 2 hours before RT; TMZ was 
given orally at least 1 hour before RT. 
 
Biomarker substudy 
Immunohistochemistry was performed basically as recommended by the manufacturers 
using a heat antigen retrieval procedure (citrate buffer) using the following antibodies and 
respective dilutions: Phospho-S6 Ribosomal Protein (Ser235/236; 1:400; #2211; Cell 
Signaling Technology [CST]), Phospho-AKT (Ser473; 1:50; D9E, #4060, CST), Phospho-
p44/42 MAPK (ERK1/2) (Thr202/Tyr204; 1:600; #4370, CST), Phospho-mTOR (Ser2448; 
1:100; 49F9, #2976, CST), Phospho-PRAS40 (Thr246; 1:25, #2997, CST), PTEN (1:50, 
138G6, #9559, CST), EGFR (1:50; DAKO M7239), and IDH1R132H (1:25; clone H14; Dianova, 
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Hamburg, Germany). The scoring was performed blinded to outcome data. Percentage of 
tumor cells with any level of positive staining were scored as follows: p-S6RP, p-AKT, p-
ERK: invalid, absent or inappropriate tissue, 0 = no positive cells, 1 = 1 - 10%, 2 = 11% - 
30%, 3 = 31% - 50%, 4 = 51% - 80%, and 5 = 81% - 100%; p-mTOR, p-PRAS40, PTEN: 
invalid, absent or inappropriate tissue, 0 = no positive cells, 1 = 1% - 10%, 2 = 11% - 50%, 3 
= 51 – 80%, 4 = 81% - 90%, 5 = 91% - 100%. For PTEN presence of vascular staining was 
used as internal control. For marker analyses the scores were dichotomized into negative 
(scores 0, 1, corresponding to 0 to10%) versus positive (scores 2 to 5, >10%). EGFR was 
evaluated according to the Hirsch score, and IDH1R132H was considered positive when 
cytoplasmic expression was detected.3,4 FISH for EGFR amplification was performed using 
Vysis LSI EGFR SpectrumOrange /CEP7 SpectrumGreen Probes (Abbott Molecular, Des 
Plaines, IL, USA). Tumors with a ratio >2 of the Average EGFR/Average CEP7 were 
classified as amplified.3 
 
Role of the funding source  
This study was funded by an academic grant from Pfizer, Berlin, Germany. Study design, 
data analysis, and data interpretation were performed collaboratively by the principal 
investigator, the study team and EORTC. The Steering Committee of the EORTC Brain 
Tumor Group oversaw the study. The principal investigator (WW) had full access to and 
reviewed all data, and had final responsibility for the decision to submit for publication. Data 
collection was performed by the investigators with monitoring performed by the EORTC; the 
database remained blinded to primary outcome variables for all parties including molecular 
marker analyses until final analysis. 
 
Statistical considerations 
For multivariable prognostic analysis, Cox models including the three clinical stratification 
factors, the P-markers and EGFR amplification were computed in each treatment arm. 
Forward stepwise method was used to select the most significant factors. Because of limited 
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sample size, this screening was done at a relaxed 15% significance level. Results are 
interpreted taking this limitation into account. To assess model goodness of fit, the Schemper 
Percentage of Explained Survival Variation (PEV) was calculated. A PEV of at least 20% was 
considered a minimum requirement for sufficiently precise predictions. Primary OS12 
analysis was performed in the per protocol population (i.e. eligible patients who started 
randomized treatment). All outcome analyses were performed on the intention-to-treat (ITT) 
population. For multivariable analyses, only samples with all molecular markers assessed 
were used. Safety was assessed on patients who started randomized treatment. 
SAS version 9.4 (SAS Institute Inc., Cary, NC, United States of America [USA]) was used for 
all analyses. The percentage of explained survival variation (PEV) was computed using the 
SAS macro RELIMPCR.  
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The median OS of 14·8 and 16·0 months observed in the temsirolimus and the TMZ arms, 
respectively, prompted us to investigate, how the OS in EORTC 26082 compared to the 
MGMT unmethylated EORTC 26981 subpopulation. This is relevant as one of the caveats of 
trials restricted to patients with MGMT unmethlylated glioblastoma is potential 
undertreatment by leaving out TMZ in the experimental group. Consistent with reports on 
enzastaurin28 or bevacizumab29, this was not the case in EORTC 26082. Looking at 
comparable trial populations (Supplementary Table 2), PFS showed no difference for any 
comparison between arms of EORTC 26082 and 26981. OS shows a significant 
improvement in the comparison of either arm of EORTC 26082 with the control arm of 
EORTC 26981 with a HR= 0·45 (0·30-0·67, p<0·0001) for RT/TMZ→TMZ and HR= 0·53 
(0·36-0·79, p=0·0015) for RT/temsirolimus. However, there was only a trend in the 
comparison between either arm of EORTC 26082 and the RT/TMZ→TMZ arm of the EORTC 
26981 trial (data not shown). 
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Supplementary Figure S1. Definition of MGMT cut-off with a safety margin. Density plot (A), 
and posterior probability plot (B) for the classification into MGMT promoter methylated (M) or 
unmethylated (U) tumors obtained by fitting a mixture model to the average log2(1000 * 
meth_MGMT/ACTB) for 602 glioblastoma samples. A gray dashed line represents the 
optimal cut-off according to the selected model (log2 ratio= 1) corresponds to a ratio value of 
2. The thresholds for lower bound of the 95% posterior probability for class U, indicated by a 
red dashed line (log2 ratio= -0.75) corresponds to a ratio value of 0.6, which has been 
defined as the cut-off with a safety margin. The upper bound 95% posterior probability for 
class M, is indicated by a green dashed line (log2 ratio= 2.72) corresponds to a ratio value 
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of 6.59. The region between is often referred to as “gray zone”, since it is associated with 
higher uncertainty.1  
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Supplementary Figure S2. Comparison of Overall Survival in patients with vs without 
markers assessments. 
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Supplementary Figure S3. Visualization of markers analyzed in the mTOR signaling 
pathway from KEGG. The markers are identified by green boxes and the representation was 
obtained using the R package pathview from the Bioconductor project.5 We determined 
phosphorylation of mTOR at serine 2448 (p-mTORSer2448) which has been shown to be 
targeted and blocked by rapamycin, a major metabolite of temsirolimus.6 Furthermore, 
phosphorylated S6 ribosomal protein (S6RPSer235/236), a direct target of the mTOR effector S6 
kinase 1, phosphorylation of AKTSer473, expression of PTEN, and phosphorylation of AKT1 
Substrate 1 (Proline-Rich) at Thr246 (p-PRAS40Thr246) were assessed. PRAS40Thr246 is 
phosphorylated by AKT1. The latter relieves inhibitory function on mTORC1.7 In addition the 
EGFR amplification status (not indicated) and phosphorylation of ERK1/2Thr202/Tyr204 that have 
been postulated as potential markers for resistance to inhibition of the PI3K/AKT/mTOR 
pathway were determined.8 
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Supplementary Figure S4. Forest plot molecular markers 
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Supplementary Figure S5.  
Complete Graphical summary of consensus cluster analysis based on the matrix obtained by 
the reconstitution of the data in using Non-linear Iterative Partial Least Squares (NIPALS) 
algorithm. The two first graphics (A et B) were used to determine the optimal cluster number. 
(A) displays the cumulative distribution functions (CDF) of the consensus for each number of 
clusters (k=2,…, 6). The Delta Area plot (B) represents the relative change in the area under 
the CDF curve comparing k and k-1. Because no strong rupture was detected in this graphic, 
we kept the cluster based on two groups (k=2) by default. (C) Display of the heatmap of the 
score table obtained after NIPALS reconstruction. The rows were ordered by the first axis of 
the PCA. The consensus classifications, and status of expression of the mutant IDH1R132H 
and amplification of EGFR were added as supplementary information. Abbreviations: mTOR 
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phosphorylated at serine 2448 (p-mTORSer2448); S6 ribosomal protein phosphorylated at 
serine 235 and 236, p-S6RPSer235/236; AKT phosphorylated at serine 473, p-AKTSer473; 
phosphatase and tensin homologue, PTEN; of AKT1 Substrate 1 (Proline-Rich) 
phosphorylated at threonin 246 (p-PRAS40Thr246) 
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Supplementary Table S1 
 
Patient’s characteristics of biomarker cohort 
Biomarker cohort, (No/Yes) 







 N (%) N (%) N (%) 
Age                                                                                                                             
 Median                                                        58.3            55.4            55.7            
 Range                                                          24.4 - 73.6       27.4 - 76.0       24.4 - 76.0      
Age (class)                                                                            
 <50yrs                                      5 (21.7)          24 (27.3)          29 (26.1)       
 >=50yrs                                    18 (78.3)          64 (72.7)          82 (73.9)       
Sex                                                                                    
 male                                       16 (69.6)          55 (62.5)          71 (64.0)       
 female                                      7 (30.4)          33 (37.5)          40 (36.0)       
Last method                                                                            
 open brain biopsy                           0 (0.0)            4 (4.5)            4 (3.6)        
 resection                                  23 (100.0)         84 (95.5)         107 (96.4)      
Patient taking anti-epileptic drug                                                     
 no                                          9 (39.1)          29 (33.0)          38 (34.2)       
 yes, non-EIAED only                        12 (52.2)          56 (63.6)          68 (61.3)       
 yes, EIAED switched                         2 (8.7)            3 (3.4)            5 (4.5)        
Currently on corticosteroids                                                           
 no                                         16 (69.6)          61 (69.3)          77 (69.4)       
 yes, stable/decreasing dose                 7 (30.4)          26 (29.5)          33 (29.7)       
 yes, increasing dose                        0 (0.0)            1 (1.1)            1 (0.9)        
WHO performance status (0-4)                                                           
 0                                          17 (73.9)          55 (62.5)          72 (64.9)       
 1                                           4 (17.4)          30 (34.1)          34 (30.6)       
 2                                           2 (8.7)            3 (3.4)            5 (4.5)        
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Supplementary Table S2 
Baseline characteristics at randomization 
 
EORTC 26981  













 N (%) N (%) N (%) N (%) N (%) 
Age                                                                                                                                 
 Median                                                        54.5            53.0            57.7            54.9            55.7             
 Range                                                          30.0 - 69.0       22.0 - 70.0       24.4 - 76.0       28.2 - 74.7       24.4 - 76.0       
 N obs                                                           58              65              55              56              111              
Sex                                                                                                                  
 male                                                               37 (63.8)          38 (58.5)          36 (65.5)          35 (62.5)          71 (64.0)        
 female                                                           21 (36.2)          27 (41.5)          19 (34.5)          21 (37.5)          40 (36.0)        
Extent of resection                                                                                                        
 open brain biopsy                                         2 (3.4)            3 (4.6)            1 (1.8)            3 (5.4)            4 (3.6)          
 resection                                                     56(96.6) 62(95.4)   54 (98.2)          53 (94.6)         107 (96.4)        
currently on corticosteroids                                                                                        
 no                                                                  17 (29.3)          20 (30.8)          37 (67.3)          40 (71.4)          77 (69.4)        
 yes    41 (70.7)          45 (69.2)          18 (32.7)          16 (28.6)          33 (29.7)        
WHO performance status (0-4)                                                                                    
 0                                                                    17 (29.3)          28 (43.1)          40 (72.7)          32 (57.1)          72 (64.9)        
 1                                                                    35 (60.3)          33 (50.8)          14 (25.5)          20 (35.7)          34 (30.6)        
 2                                                                     6 (10.3)           4 (6.2)            1 (1.8)            4 (7.1)            5 (4.5)          
** there is an imbalance between arms for WHO PS.  
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